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Gene Transfer System Using Biopolymer-Coated
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Abstract—Development of a simple method for converting
the lipid envelope of an inactivated virus to a gene transfer
vector was achieved a couple years ago in the medical school
of Osaka University. Hemagglutinating virus of Japan (HVJ;
Sendai virus) envelope (HVJ-E) vector was constructed by incor-
porating plasmid DNA into inactivated HVJ particles. This HVJ
envelope vector introduced plasmid DNA efficiently and rapidly
into various cell lines, including cancer cells and several types
of primary cell culture. In the present study, efficiency of gene
transfer was found to be greatly enhanced by application of a
magnetic field. Therefore, we developed a new type of magnet for
magnetically enhancing and targeting gene transfection system
by using vectors associated with ferromagnetic particles coated
with positively/negatively charged biopolymers, which can help to
enhance and target gene delivery with higher efficiency. For the
transfection experiment in vitro, the HVJ-E vector was mixed with
ferromagnetic particles coated with biopolymer and this mixture
was added to cultured cells which were set up under the perma-
nent magnet. The effect of the dose of the ferromagnetic particles
on the transfection efficiency was discussed. In order to clarify the
effect of magnetic field gradient on the accumulation possibility
of the magnetic particles and the accuracy of the targeted site in
the blood vessels, calculation of the applied magnetic force for the
ferromagnetic particles inside the blood vessel was also performed.
Index Terms—Drug delivery system, gene therapy, HVJ-E, mag-
netic field effects, magnetic nanoparticle, magnetic targeting.
I. INTRODUCTION
PROGRESS in gene therapy requires a novel drug deliverysystem (DDS). To enhance the transfection efficiency, we
developed a hybrid vector utilizing the envelop of HVJ (hemag-
glutinating virus of Japan). The HVJ-E vector for rapidly tar-
geting is still insufficient for rapid and specific accumulation
of active vectors in target tissues. One solution is to engineer
the surface proteins of viral vectors or to couple targeting lig-
ands to viral as well as nonviral vectors, which might further
improve tissue selectivity [1]–[4]. Thus, we examined modifi-
cation of the membrane surface of HVJ to achieve an improve-
ment. In this study, we focused on magnetic nanoparticles, such
as maghemite, with an average size of 30nm, which can attach
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to vectors incorporating plasmid DNA, ligonucleotide or protein
and transfer into cells by cell fusion [5]. These prepared mag-
netic vectors can be positionally regulated by a magnetic force.
Magnetic nanoparticles basically consist of oxidized Fe, which
is commonly used as a supplement for the treatment of anemia.
We hypothesized that the association of magnetite and HVJ-E
technology could allow the rapid attachment of HVJ-E and cells
by application of a magnetic force, leading to enhanced transfec-
tion efficiency. Moreover, magnetic nanoparticles can be mod-
ified with several chemical compounds to allow modification
of the charge, size, and affinity. In addition, there is increasing
interest in using magnetic resonance imaging (MRI) to monitor
the in vivo behavior of proteins labeled with magnetic nanoparti-
cles [6], [7]. Indeed, magnetic nanoparticles were recently used
for gene transfection, because magnetic targeting exploits para-
magnetic particles as drug carriers, guiding their accumulation
in target tissues with strong local magnetic fields [8], [9]. Here,
the present study demonstrated that modification of magnetic
nanoparticles with protamine sulfate enhanced the transfection
efficiency associated with HVJ-E system in cultured cells in
vitro.
Calculation of the applied magnetic force for the ferromag-
netic particles inside the blood vessel was also performed using
a model system of blood vessels in order to clarify the effect of
magnetic field gradient on the accumulation possibility of the
magnetic particles and design the practical magnet with high
accuracy of the targeted site in the blood vessels.
II. MATERIALS AND METHODS
A. Preparation of HVJ-E Vector and Plasmid DNA
HVJ-E vector was obtained from Ishihara (Osaka, Japan).
Basically, aliquots of the inactivated virus (6 AU) were sus-
pended in 40 TE solution (10 mM Tris—Cl, pH 8.0, 1 mM
EDTA) and mixed with plasmid DNA (30 ), and 0.3% Triton
X. The mixture was centrifuged at 18 500 g for 15 min at 4
degrees Celsius. After washing the pellet with 1 ml balanced
salt solution (BSS; 10 mM Tris—Cl, pH 7.5, 137 mM NaCl,
and 5.4 mM KCl) to remove the detergent and unincorporated
DNA, the envelop vector was suspended in 300 BSS. The
titer of the inactivated virus was modified according to each
experiment. pEGFP-C1 was purchased from Clontech (CA,
USA). pCMV-luciferase-GL2 was constructed by cloning the
luciferase gene from the pGL2-promoter vector (Promega,
Madison, WI, USA) into pcDNA3 (5.4 kb) (Invitrogen, San
Diego, CA, USA). Plasmids were purified with a Qiagen
1051-8223/$20.00 © 2006 IEEE
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plasmid isolation kit (Hilden, Germany). FITC-oligodeoxynu-
cleotides (ODN) (random sequence) were purchased from
Gene Design (Osaka, Japan).
B. Preparation of Magnetic HVJ-E Vector
Commercially available maghemite particle (NanoTek
-Fe2O3, C.I. Kasei) was used for the preparation of magnetic
HVJ-E vector in the present study. The averaged primary
size of maghemite particle used in this study was 29 nm. The
particles were mixed with protamine sulfate or heparin solution
to prepare magnetic nanoparticles modified with biopolymers,
which consist of cationic or anionic polymer adsorbing onto
ferromagnetic nanosized particles. The prepared magnetic
nanoparticles were then mixed with HVJ-E vector to provide
ferromagnetism to the HVJ-E vector.
C. Measurement of Zeta Potential of Maghemite Particles
Zeta potential is an important parameter in understanding
electrostatic colloidal dispersion stability. Zeta potential is the
charge that a particle acquires in a particular medium. It is de-
pendent upon the pH, ionic strength and concentration of a par-
ticular component. The mobility of particles undergoing elec-
trophoresis is measured by the technique of laser Doppler elec-
trophoresis. This measured electrophoretic mobility is then con-
verted to zeta potential using established theories. In order to
know the surface property of the magnetic vector, the zeta poten-
tial of the particles with and without surface modification was
determined (Zetasizer Nano ZS, Malvern, U.K.). Mixtures of
magnetite particles with and without surface modification with
protamine sulfate or heparin and the prepared magnetic HVJ-E
vector were used.
D. Gene Transfer in vitro
For in vitro transfection, cells were prepared in
6-well culture dishes 1 day before transfection experiment.
HVJ-E vector (1 or 0.2 AU) containing luciferase plasmid
(GL2: 5 or 1 ) or FITC-ODN (2 or 0.4 ) was mixed with
various concentrations of maghemite and DMEM containing
10% FCS, and added to cells cultured in DMEM supplemented
with 10% FBS on a magnetic sheet.
E. Magnetic Sheet and Cultured Dish
The magnetic sheet was placed under the 6-well culture dish.
The magnetic field gradient is one of the parameters affecting
the strength of the magnetic force applied to the magnetic vec-
tors to sediment to the cell surface. Magnetic field measure-
ments were performed by Hall detector to calculate the magnetic
field gradient. A 3-axis Hall effect teslameter (MetroLab THM
7025, METROLAB Instruments SA, Switzerland) was used to
measure the magnetic field. The averaged value of the measured
magnetic field at the sheet surface was approximately 1.2 mT
and the calculated value of the field gradient was 0.17 T/m. After
10 min of incubation at 37 degrees Celsius under 5% , the
medium was replaced and the cells were cultured overnight be-
fore examination of gene expression. GFP expression or FITC
ODN transfected cells were observed under a fluorescence mi-
croscope.
Fig. 1. Schematic of the controlling particle system utilized for modeling the
targeting of magnetic particle inside the blood vessel using by the magnetic
force. 2R is a diameter of the blood vessel. The final position [X ;Y ] is cal-
culated based on the equations of drug force (F ) and magnetic force (F )
using a recursive formulae.
F. Luciferase Activity and LDH Release
Luciferase activity was measured following the manufac-
turer’s instructions (Promega Madison) [10]. Twenty-four
hours after transfection, cells were washed once with PBS and
then incubated with lysis buffer. The protein concentration
was determined using the Bio-Rad protein assay adapted for
use in a 96-well plate. After 20 cell extract was mixed with
100 luciferase assay reagent (Promega, Madison), the light
produced was measured for 2 s using a luminometer. The extent
of cell death was assessed using a commercially available kit
(Wako, Osaka) to measure released LDH activity from dead
cells according to previous reports [11], [12], because loss of
cell membrane integrity was observed in both necrotic and
apoptotic cells. The percentage of LDH release was calculated
relative to the maximum cell death of cells treated with 1%
Triton X-100 for 10 min.
G. Calculation of the Magnetically Targeted Ferromagnetic
Particle in Blood Vessel
A 2-D schematic of particle control system utilized for mod-
eling the targeting of magnetic particle by the magnetic force
arising from the magnet placed outside the blood vessel is rep-
resented in Fig. 1. Forces that act on the magnetic particle are
shown in this figure. The particle feels viscous drag force when
it begins to move. On the other hand, magnetic force acts on
floating ferromagnetic particles when the particles in the blood
vessel are placed under the magnetic field.
When the magnetic particle is assumed to be spherical, energy
U arising from magnetic force is as follows:
(1)
where and are magnetic susceptibilities of the particle
and fluid, respectively. And b is a radius of the magnetic par-
ticle. Therefore, magnetic force acts the magnetic particle
as follows:
(2)
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Magnetic force is product of magnetic field strength and mag-
netic gradient.
When velocity of the magnetic particle is different from
the blood flow velocity , the particle is subjected to the drag
force FD from the fluid, and thus Stokes’s expression can be
used on the magnetic particle
(3)
where is a viscous coefficient of the blood.
The vessel walls are assumed to be two parallel planes also
placed perpendicular to the plane of the figure, as shown. The
blood accesses the vessel wall from the initial position located
in the left side in this figure with a velocity defined by a par-
abolic profile of initial velocity and it transports the mag-
netic particle to be captured by the wall. Finally, the magnetic
particle is subjected to a homogeneous magnetic field po-
sitioned perpendicular to the blood flow. The model accounts
for magnetic force and hydrodynamic force while neglects the
effect of gravity force as well as any effect due to the vessel
walls. The fluid dynamics in the blood vessel is described by the
equations of (2) and (3) mentioned above for an incompressible
Newtonian fluid.
The trajectory of the magnetic particle is calculated by using
(2) and (3). When we initially set the magnetic particle in the
blood vessel with a velocity defined as an initial velocity
at the location, shown in Fig. 1, a particle
acceleration, at the is calculated using
the following:
(4)
where is a mass of the magnetic particle. The 2nd position,
velocity, and acceleration are calculated using the following:
(5)
(6)
(7)
Therefore, the th position, velocity, and acceleration after th
infinitesimal time are represented by
(8)
(9)
(10)
The calculation was made using recursive formulae for the
particle with a diameter of 2 of maghemite under the various
magnetic gradients from 1 T/m to 500 T/m in the blood flow
(averaged flow velocity: 10 cm/s).
Fig. 2. Transfection efficiency and cell toxicity of maghemite-associated
HVJ-E vector (1 HAU) containing the luciferase expression plasmid (5 g) was
transferred to BHK-21cells with various concentrations of protamine sulfate
coated maghemite. The final concentrations of PS and PS-coated maghemite
were as follows: 100 g=ml PS, 1, 10, and 100 g=ml PS-coated maghemite.
III. RESULTS AND DISCUSSION
A. Magnetic Transfection Efficiency and Cell Toxicity
To evaluate the HVJ-E vector system mixed with maghemite,
we measured luciferase activity to evaluate transfection activity
and LDH release to evaluate cell toxicity after transfection.
We mixed several doses of maghemite (from 1 mg/ml to
100 mg/ml) with HVJ-E vector infusing luciferase plasmid.
However, unexpectedly, we did not find any improvement in
transfection efficiency as assessed by luciferase activity in
BHK-21 cells, whereas a high dose of maghemite induced cell
death as assessed by LDH release (results not shown). From
these results, we speculated that there might be a close asso-
ciation, such as electrostatic interaction, between HVJ-E and
maghemite. Since we previously knew that protamine sulfate
(PS), a low-molecular-weight naturally polycationic peptide
(ca.4000 Da), enhanced the transfection efficiency based on
the HVJ-E vector in an in vitro culture system [5], we coated
the surface of maghemite with PS. After modification with PS,
the zeta potential of maghemite was changed to 23.8 1.8
mV from 17.5 1.6 mV, which suggests that surface coating
of maghemite enhanced its cationic charge. Interestingly, a
mixture of PS-coated maghemite with HVJ-E vector signifi-
cantly enhanced the transfection efficiency in a dose-dependent
manner (Fig. 2, ), which clearly indicated that the
magnetic force can enhance the transfection efficiency. One
reason of this effect is probably ascribed to enhancement of
the rapidness of the magnetic vector approaching toward the
BHK-21 cell surface. However, induction of cell death was still
detected at a high dosage.
B. Calculations for Designing New Magnet for Gene Therapy
The calculated particle trajectory was shown in Fig. 3. This
figure can allow us to realize how strong magnetic gradient is
needed to accumulate the magnetic particle on the wall of the
blood vessel. For example, when we apply the magnetic gradient
of 500 T/m, a magnetic particle can be easily accumulated on
the wall. Simultaneously, this graph can give us the information
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Fig. 3. Calculated particle trajectory under blood flow (flow velocity: 10 cm/s).
Y-axis is a displacement from the center of the blood vessel to the wall. X-axis
is a displacement in flow direction from the initial position to the final position.
Fig. 4. Relation between a displacement of the magnetic particle in flow direc-
tion and magnetic gradient for 2 m magnetic particle under flow velocity of
10 cm/s.
how long distance will be required to accumulate the particle on
the wall of the blood vessel even in blood flow.
Fig. 4 clearly shows an effect of the magnetic gradient on the
particle displacement in the blood flow. The displacement does
not change so much in the range of magnetic gradient over 100
T/m.
IV. CONCLUSION
The present study demonstrated that modification of mag-
netic nanoparticles with protamine sulfate enhanced the
transfection efficiency associated with HVJ-E system in cul-
tured cells in vitro. This result can open the way for developing
a novel gene therapy technique using magnet.
Calculation of the applied magnetic force for the ferromag-
netic particles inside the blood vessel was also performed using
a model system of blood vessels in order to clarify the effect of
magnetic field gradient on the accumulation possibility of the
magnetic particles and design the practical magnet with high ac-
curacy of the targeted site in the blood vessels. The calculated
results show the possibility of this technology and we can cal-
culate the targeting site in the blood vessel.
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